Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s DNA!’ said Prof. Dehmeshki, Chief Technology Officer.

At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘IAG brings artificial intelligence in a meaningful way to the imaging process. This is the future of imaging – drives down cost and improves quality of analysis.  As images are used more for statistically meaningful endpoints, IAG has proven, validated, AI algorithms. The IAG platform and service model fits exactly with pharma efforts to be digital organizations, allowing seamless data ingestion capabilities and real time data access for analysis and decision making.’, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

News
Events

New Article on Genetic Differences in patients with Hip and Knee OA

New Article on Genetic Differences in patients with Hip and Knee OA

Genome-wide association meta-analysis of knee and hip osteoarthritis uncovers genetic differences between patients treated with joint replacement and patients without joint replacement

Genome-wide association meta-analysis indicate differences in genetic associations between knee and hip osteoarthritis depending on joint replacement status. Genetic correlations with pain phenotypes tended to be stronger in the non-surgical groups. For the surgical phenotypes, 10 novel variants were identified, including genes involved in autophagy (rs2447606 in ATG7) and mechanotransduction (rs202127176 in PIEZO1).

Title: Genome-wide association meta-analysis of knee and hip osteoarthritis uncovers genetic differences between patients treated with joint replacement and patients without joint replacement

Journal: Annals of the Rheumatic Diseases

Authors: Cecilie Henkel, Mikael Boesen and Anders Troelsen

Access Publication Online: http://dx.doi.org/10.1136/ard-2022-22319

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s NDA!’ said Prof. Dehmeshki, Chief Technology Officer.

‘At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘We see DYNAMIKA as a unique bridge between clinical trials and clinical practice worlds. It is not trivial to translate the results of clinical trials into clinical practice. Here at IAG, we can power our pharmaceutical partners to do just that, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

News
Events

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Many congratulations to Prof. Sotirios Bisdas, IAG’s Therapeutic Area Head, who received the Neuroradiologist of the Year Award in 2022, supported by the 11th International Day of Radiology #IDoR2022.

Our warmest congratulations to Prof. Bisdas, the true industry innovator and one of the most inspiring and dedicated professionals of our times!

‘Being successful in radiology takes hard work. One can’t afford to stay on autopilot in today’s rapidly changing research environments and still expect to remain on top. I believe in a culture of inclusion, purpose, support, and empathy for our consultants, academics, and clinical scientists putting patients in the centre of our work,’ said Prof. Bisdas.

Prof. Sotirios Bisdas, the Head of IAG’s Neuro-Oncology and Neuro-Degeneration is also a consultant neuroradiologist and MRI lead in the Department of Neuroradiology at the National Hospital for Neurology in London, UK, senior lecturer in neuroradiology at the Institute of Neurology University College London, and professor of radiology at Eberhard Karls University in Tübingen, Germany.

He finished his MD thesis in psychiatry after joint studies at University of Athens, Greece and University of Mainz, Germany. Dr  Bisdas was trained in Radiology and Neuroradiology at Hannover Medical School, University of Frankfurt, and University of Tübingen. He has completed a post-doctoral scholarship in Neuroradiology Research at the Medical University of South Carolina, USA. He holds a MSc degree in “Advanced Oncology” from University of Ulm, Germany and is also fellow of the European Society of Head and Neck Radiology. His expertise fields include advanced CT, intraoperative MRI, advanced and functional MRI and molecular MR-PET imaging in brain diseases.

He has authored more than 130 peer-reviewed publications (h-index > 30) and seven book chapters.

Currently, he is clinical lead of the flagship program in neuro-oncology, a joint initiative of the Institute of Healthcare Engineering and the National Hospital of Neurology and Neurosurgery. Dr Bisdas serves as member of the editorial board of several leading journals in radiology and neuroradiology, is reviewer for leading journals in neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

News
Events

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG team and Julia O’Lynn, IAG’s Director of Bio Innovation and Strategic Partnerships, will be attending the Society of Neuro-Oncology (SNO 2022) 27th Annual Meeting and Educational Day in Tampa, Florida, on November 16 – 20, 2022.

IAG’s team will be meeting with biotech companies and addressing their challenges including trial design, dealing with pseudo-progression, finding optimal endpoints to demonstrate novel therapeutics’ efficacy. We will speak about our platform DYNAMIKA and use of Artificial Intelligence in neuro-oncology trials and explore how IAG’s novel strategies, including advanced imaging biomarkers and AI can support precision medicine and drug development.

Together with our biotech partner CNS Pharmaceuticals Inc., we will be presenting the preliminary results from a  randomized, controlled trial of Berubicin.

Currently, 31 patients are enrolled with 21 in the Berubicin arm and 10 in the Lomustine arm. Trial design: https://clinicaltrials.gov/ct2/show/NCT04762069 The data available shows that Berubicin and Lomustine arms are presently balanced with relatively comparable safety profiles. This study will evaluate the efficacy of this novel drug and potentially provide therapeutic options for patients after first-line therapy.  An updated profile of the patient population, safety, and initial efficacy will be presented.

POSTER INFORMATION

A randomized, controlled trial of Berubicin, a topoisomerase II poison that crosses the blood-brain barrier (BBB), after first-line therapy for glioblastoma multiforme (GBM): Preliminary Results, Authors: S. Silberman, J. O’Lynn, O. Kubassova

If you are not attending and would like to request a poster or to schedule a call: imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

About SNO, the Society for Neuro-Oncology

The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. click here.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

A collaboration between IAG, Image Analysis Group, the University of Leeds, and Prof. Francesco Del Galdo brings a new AI-driven endpoint into clinical trials.

For immediate release: 21 October 2022

Digital Artery Volume Index (DAVIX©) is a novel quantitative MRI-based scoring for the assessment of the blood flow in the arteries.

DAVIX© has been validated as a predictor of the onset of Digital Ulcers in Systemic Sclerosis patients. This innovative methodology is based on the Time-of-Flight Magnetic Resonance Imaging (MRI) angiography and allows to quantitatively assess digital arterial blood flow.

Thus, predicting the onset of Digital Ulcers (DUs) in Systemic Sclerosis (SSc) patients.

The methodology was developed as part of IAG’s DYNAMIKA cloud platform and is now accessible for use in clinical trials and clinical practice for research use. DAVIX© is being deployed by biotech and pharmaceutical companies in global clinical trials as a surrogate outcome measure of SSc vascular disease activity.

This robust methodology can be delivered to clinical sites, with over 100 imaging sites around the world already acquiring the specific MRI data to allow for the assessment of SSc patients with DAVIX©.

DAVIX© is the first MRI quantitative measure of vascular disease in Systemic Sclerosis. Building on its predictive value for active vascular disease, it is now tested in randomised clinical trials as stratification tool for vascular disease and as a surrogate endpoint for vasoactive interventions,” said Professor Francesco Del Galdo, University of Leeds.

The proprietary name of the endpoint DAVIX© has been copyrighted by the University of Leeds, with a lifetime licence assigned to IAG, Image Analysis Group.

“We look forward to seeing how this unique endpoint will help accelerating the speed of pharmaceutical R&D and most importantly improve therapeutic success for patients,“  said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

Neointima proliferation results in vascular wall thickening and gradual loss of luminal patency and is a key pathological feature of Systemic Sclerosis. It is a recognised culprit pathological lesion in Digital Ulcers, pulmonary hypertension and renal crisis.

We are delighted with the results of this collaboration. DAVIX© fits perfectly with IAG’s suite of advanced Artificial Intelligence (AI)-supported imaging methodologies and our strategy to make DYNAMIKA™ the leading image management platform for forward thinking drug developers, said Simon Hart, IAG’s Bio-Partnering Director.

IAG’s has brought technical capabilities and over 15 years of operational experience helping to optimize and standardize DAVIX© in clinical trials. This is a great compliment to all IAG’s teams involved into developing and deploying our Artificial Intelligence methodologies, across hundreds of globally distributed clinical sites, built on our DYNAMIKA™, IAG’s proprietary secure cloud based medical image management and review platform, “ added Prof. Jamshid Dehmeshki, CTO of IAG.  

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

News
Events

New Article on Computer‐Assisted Image Analysis Published in ACR Open Rheumatology

New Article on Computer‐Assisted Image Analysis Published in ACR Open Rheumatology

Computer-assisted Image Analysis in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis

AI-based methods demonstrate feasibility, reliability and validity when utilized to quantify MRI pathologies of peripheral joints in patients with inflammatory arthritis. Computer-aided evaluation could be considered as an alternative to conventional observer-based methods.

Title: Computer-assisted Image Analysis in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis

Journal: ACR Open Rheumatology: ACROR-21-226.R1

Authors: Arya Haj-Mirzaian, Olga Kubassova, Mikael Boesen, John Carrino and Paul Bird

Access Publication Online: https://journals.lww.com

 

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Live presentation DDW 2022: AI and Precision Medicine in Ulcerative Colitis

Live presentation DDW 2022: AI and Precision Medicine in Ulcerative Colitis

Live presentation DDW 2022: AI and Precision Medicine in Ulcerative Colitis

Join Dr Olga Kubassova, IAG’s CEO, Simon Hart, IAG’s Bio-partnering Director, and key opinion leader Professor Laurent Peyrin-Biroulet (Nancy University Hospital, France) during a live presentation of our collaborative project with Takeda Pharmaceuticals International AG.

“An Artificial Intelligence driven scoring system to measure histological disease activity in Ulcerative Colitis”

Date: 24 May 2022,  2:30 pm PDT

In this live presentation, Professor Laurent Peyrin-Biroulet will discuss the application of IAG’s Artificial Intelligence (AI) driven assessment of histopathology ulcerative colitis images, in the first of a series of collaborative projects between IAG and Takeda.

Join IAG at the presentation, or if you are not attending, schedule a call: imaging.experts@ia-grp.com

About the project

The collaboration is supported by prominent clinical centres and opinion leaders, including sites in Switzerland, France, Canada, USA, Israel, and Portugal.

IAG and Takeda have been working together since 2019 and have developed a novel Artificial Intelligence (AI)-powered method for the assessment of histopathology ulcerative colitis images. The tool will potentially allow practising gastroenterologists to evaluate disease activity with an automated method that is accurate, reproducible and reliable in UC patients. To date, the AI Tool has been trained and tested on 200 images, showing performance comparable to a human expert. As the next step, the partners are engaging eight world-leading sites, who will test the AI Tool in their clinical practices.

Together with our commercial and academic partners, we are excited to be in the position to advance clinical decision-making by bringing better technologies into the play, said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

‘Augmenting clinical decision-making with AI in the field of histopathology has the potential to bring great value for management of patients with ulcerative colitis.  Our AI Tool’s ability to provide additional information on the disease state and patient response to a new treatment in real-time gives us ability to gain more insights and make better and faster decisions,’ said Prof. Laurent Peyrin-Biroulet, Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy.

As part of our 30-year commitment to gastroenterology, we recognize the importance of collaborations with digital health leaders, such as IAG, to identify and pursue cutting edge technologies to advance the care of patients.  We see great potential in this initiative and are excited to enter into the next phase of research using deep learning models and AI to support gastroenterologists’ in their patient care”, said Dr. Shashi Adsul, Sr. Director, Global Medical Unit Head at Takeda Pharmaceuticals International AG.

About DDW

Digestive Disease Week (DDW) is the most prestigious meeting in the world for GI professionals providing an unparalleled opportunity to delve into exciting new developments with leaders in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events

Meet IAG’s Team at DDW 2022, San Diego

Meet IAG’s Team at DDW 2022, San Diego

Meet IAG’s Team at DDW 2022, San Diego

Dr. Olga Kubassova, IAG’s CEO, and Simon Hart, IAG’s Bio-partnering Director, will be attending the Digestive Disease Week 2022 (DDW 2022) conference in San Diego, on May 21 – 24, 2022.

IAG’s team will be meeting with key biotech companies and addressing the challenges they face in pharmaceutical trials to explore IAG’s novel strategies, including advanced imaging biomarkers and Artificial Intelligence in precision medicine and drug development.

If you are not attending, schedule a call: imaging.experts@ia-grp.com

IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

Discover our risk assessment and management strategies to overcome the challenges in your trial by contacting IAG at imaging.experts@ia-grp.com

About DDW

Digestive Disease Week (DDW) is the most prestigious meeting in the world for GI professionals providing an unparalleled opportunity to delve into exciting new developments with leaders in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events

Meet IAG’s Team at EULAR 2022, Copenhagen

Meet IAG’s Team at EULAR 2022, Copenhagen

Meet IAG’s Team at EULAR 2022, Copenhagen

Dr. Olga Kubassova, IAG’s CEO, will be attending the European Congress of Rheumatology (EULAR 2022) in in Copenhagen, on June 1 – 4, 2022.

IAG’s team will be meeting with key biotech companies and addressing the challenges they face in pharmaceutical trials to explore IAG’s novel strategies, including advanced imaging biomarkers and Artificial Intelligence in precision medicine and drug development.

POSTER INFORMATION

Use of Artificial Intelligence and cloud-based infrastructure to improve the speed and accuracy of eligibility reads in osteoarthritis trials. POS1127

M. Boesen, C. Pereira da Costa, J. O’Lynn, A. Patterson, D. Kessler, O. Kubassova

If you are not attending, schedule a call: imaging.experts@ia-grp.com

IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

Discover our risk assessment and management strategies to overcome the challenges in your trial by contacting IAG at imaging.experts@ia-grp.com

About EULAR

European Congress of Rheumatology (EULAR 2022) is one of the the most prestigious meetings in the world for rheumatology providing a forum of an unparalleled opportunity to the highest standard for scientific, both clinical and basic, educational and social exchange between professionals.

To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events